Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabionCD20 vs MabThera in DLBCL
NCT02617485Phase 3Completed
- Sponsor
- Mabion S.A.
- Start
- Dec 2015
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of MabionCD20 in diffuse large B-cell lymphoma (DLBCL), sponsored by Mabion S.A.. Started Dec 2015; status: completed.
02
Drugs
MabionCD20
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02617485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617485.